Paediatric Respiratory Reviews
Volume 11, Issue 3 , Pages 149-153 , September 2010

Pulmonary hypertension in chronic neonatal lung disease

  • Michael Farquhar

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Respiratory Medicine, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, Sydney, NSW, Australia 2145. Tel.: +61 2 9845 3397; fax: +61 2 9845 3396.
    • ,
  • Dominic A. Fitzgerald

References 

  1. Smith VC, Zupancic JA, McCormick MC, et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr. 2005;146:469–473
  2. Maclean JE, Fitzgerald DA. A rational approach to home oxygen use in infants and children. Paediatr Respir Rev. 2006;7:215–222
  3. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998;53:81–94
  4. Fitzgerald D, Evans N, Van Asperen P, et al. Subclinical persisting pulmonary hypertension in chronic neonatal lung disease. Arch Dis Child Fetal Neonatal Ed. 1994;70:F118–F122
  5. De Visser Y, Walther FJ, Laghmani EH, Boersma H, van der Laarse A, Wagenaar GTM. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respiratory Research. 2009;10:30
  6. ATS Documents. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003; 168:356–396.
  7. Khemani E, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120:1260–1269
  8. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623–661
  9. Bush A, Busst CM, Knight WB, Hislop AA, Haworth SG, Shinebourne EA. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child. 1990;65:739–745
  10. Shennan AT, Dunn M, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirements in the neonatal period. Pediatrics. 1988;82:527–532
  11. Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child. 2008;93:620–625
  12. Mourani PM, Sontag M, Younoszai A, Ivy D, Abman SH. Clinical Utility of Echocardiogrpahy for the Diagnosis and Management of Pulmonary Vascular Disease in Young Children with Chronic Lung Disease. Pediatrics. 2008;121:317–325
  13. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6:750–756
  14. Skinner JR, Stuart AG, O'Sullivan J, Heads A, Boys RJ, Hunter S. Right heart pressure determination by Doppler in infants with tricuspid regurgitation. Arch Dis Child. 1993;69:216–220
  15. Evans NJ, Archer LNJ. Doppler assessment of pulmonary artery pressure during recovery from hyaline membrane disease. Arch Dis Child. 1991;66:802–804
  16. Evans NJ, Archer LNJ. Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child. 1991;66:6–11
  17. Kosturakis D, Goldberg SJ, Allen HD, Loebor C. Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease. Am J Cardiol. 1984;53:1110–1115
  18. Bancalari E, Wilson-Costello D, Iben SC. Management of infants with bronchopulmonary dysplasia. Early Hum Dev. 2005;81:171–179
  19. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Current issues. Pediatr Clin North Am. 1994;41:277–315
  20. Tay-Uyboco JS, Kwiatkowski K, Cates DB, et al. Hypoxic airway constriction in infants of very low birth weight recovering from moderate to severe bronchopulmonary dysplasia. J Pediatr. 1989;115:456–459
  21. Presberg KW. Dincer HE Pathophysiology of pulmonary hypertension due to lung disease. Curr Opinion in Pulmonary Medicine. 2003;9:131–138
  22. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology. 2007;91:283–290
  23. Abman SH. The dysmorphic pulmonary circulation in bronchopulmonary dysplasia: a growing story. Am J Respir Crit Care Med. 2008;178:114–115
  24. Askie LM, Henderson-Smart DJ, Irwig L, et al. Oxygen saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959–967
  25. Fitzgerald DA, Massie RJH, Nixon G, Jaffe A, Wilson A, Landau LI, et al. Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. Position Statement from the Thoracic Society of Australia and New Zealand. MJA. 2008;189:578–582
  26. Balfour-Lynn IM, Field DJ, Gringras P, et al. BTS guidelines for home oxygen in children. Thorax. 2009;64(Suppl 2):ii1–26
  27. Sekar KC, Duke JC. Sleep apnea and hypoxemia in recently weaned premature infants with and without bronchopulmonary dysplasia. Pediatr Pulmonol. 1991;10:112–116
  28. Fitzgerald D, Van Asperen P, Leslie G, et al. Higher SaO2 in chronic neonatal lung disease: does it improve sleep?. Pediatr Pulmonol. 1998;26:235–240
  29. Mourani PM, Ivy DD, Rosenberg AA, et al. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr. 2008;152:291–296
  30. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed. 2002;87:F15
  31. Kotecha S, Allen J. Oxygen therapy for infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002;87:F110–114
  32. Subhedar NV, Shaw NJ. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2000;82:F243–248
  33. Fitzgerald DA, Rohlicek C, Gottesman R, Davis GM. Infants with severe bronchiolitis: Is there a role for inhaled nitric oxide?. J Paed Child Health. 2001;37:64–66
  34. Gray P, Rogers Y. Are infants with bronchopulmonary dysplasia at risk for sudden infant death syndrome?. Pediatr. 1994;93:774–777
  35. Poets CF, Samuels MP, Southall DP. Epidemiology and pathophysiology of apnoea of prematurity. Biol Neonate. 1994;65:211–219
  36. Krishnan U, Krishnan S, Gewitz M. treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol. 2008;1082–1086
  37. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639–646
  38. Garg UC, Hassed A. Nitric oxide generating vasodilators and 8-bromo-guanosine monophosphate inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777
  39. Finer NN, Barrington KJ. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2006;1:CD000509
  40. Weissmann N, Gerigk B, Kocer O, et al. Hypoxia induced pulmonary hypertension: different impact of iloprost, sildenafil and nitric oxide. Respir Med. 2007;101:2125–2132
  41. Erickson S, Reyes J, Bohn D, et al. Sildenafil (Viagra) in Childhood and Neonatal Pulmonary Hypertension. J Am Coll Cardiol. 2002;39(Suppl):S402
  42. Humpl T, Reyes JT, Holtby H, et al. Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study. Circulation. 2005;111(24):3274–3280
  43. Karatea AA, Bush A, Magee AG. Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension. Int J Cardiol. 2005;100(2):267–273
  44. Carter NJ, Keating GM. Bosentan: In Paediatric Patients with Pulmonary Arterial Hypertension. Pediatr Drugs. 2010;12:63–73
  45. Price LC, Howard LSGE. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs. 2008;8:171–185
  46. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29:469–475
  47. Porhownik NR, Al-Sharif H, Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008;15:427–430
  48. Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: role of palivizumab. Paediatr Resp Rev. 2009;10:143–147
  49. Smith LC, van Asperen PP, McKay KO, Selvadurai H, Fitzgerald DA. Reduced exercise capacity in children born very preterm. Pediatrics. 2008;122:e287–293

PII: S1526-0542(10)00037-0

doi: 10.1016/j.prrv.2010.05.001

Paediatric Respiratory Reviews
Volume 11, Issue 3 , Pages 149-153 , September 2010

Article Tools